Anna Litvak, MD
Medical Oncology · Livingston, NJNPI 1326319302
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,990 of the $19,541 with a category attached, or 86.9%. 12 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 51.6% of the total. Reporting peaked in 2022 at $6,210 and has fallen 98.8% since, to $75 in 2025.
Across 61 payments — averaging $320.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$10K
- AstraZeneca$4K
- Novartis$2K
- Daiichi Sankyo Inc.$2K
- Stemline Therapeutics Inc.$1K
- Amgen$100
- plus $162 from 6 others
Across 74 payments — averaging $25,842 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.7M
- Daiichi Sankyo Inc.$68K
- Radius Health, Inc.$56K
- Macrogenics, Inc.$44K
- Stemline Therapeutics Inc.$9K
- Eli Lilly$500
- plus $64 from 1 others
What the payments were for
- Consulting fees$16,99087%
- Food & beverage$4782%
- Education$1241%
- Gifts$9675%
- Other$9825%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $10,082 |
| AstraZeneca(2 entities) | 8 | $3,981 |
| Novartis | 34 | $2,194 |
| Daiichi Sankyo Inc. | 1 | $1,943 |
| Stemline Therapeutics Inc. | 1 | $1,080 |
| Amgen | 1 | $100 |
| Eisai Inc. | 2 | $45 |
| Foundation Medicine, Inc. | 1 | $40 |
| Gilead | 2 | $29 |
| Tolmar, Inc. | 1 | $21 |
| Novocure Inc. | 1 | $16 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,541 in reported general payments places this provider in the 80th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 12 | $190,393 |
| Anastrozole | 216 | $5,548 |
| Exemestane | 16 | $3,120 |
| Letrozole | 81 | $2,427 |
| Tamoxifen Citrate | 20 | $537 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Livingston
- Jennifer WagmillerLivingston$10K
- Andrew BrownLivingston$4K
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.